Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia
Gespeichert in:
| Autor*in: |
Mohd Kasim, N.A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Übergeordnetes Werk: |
Enthalten in: No title available - 315.2020, e42- |
|---|---|
| Übergeordnetes Werk: |
volume:315 ; year:2020 ; pages:42 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.atherosclerosis.2020.10.135 |
|---|
| Katalog-ID: |
ELV052543862 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV052543862 | ||
| 003 | DE-627 | ||
| 005 | 20230624184538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2020.10.135 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica |
| 035 | |a (DE-627)ELV052543862 | ||
| 035 | |a (ELSEVIER)S0021-9150(20)30717-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohd Kasim, N.A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| 264 | 1 | |c 2020 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 700 | 1 | |a Nazli, S.A. |4 oth | |
| 700 | 1 | |a Muhmad Hamidi, M.H. |4 oth | |
| 700 | 1 | |a Chua, Y.A. |4 oth | |
| 700 | 1 | |a Sani, H. |4 oth | |
| 700 | 1 | |a Kasim, S.S. |4 oth | |
| 700 | 1 | |a Mohd Nawawi, H. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t No title available |g 315.2020, e42- |w (DE-627)ELV012595616 |w (DE-600)1-9150 |7 nnns |
| 773 | 1 | 8 | |g volume:315 |g year:2020 |g pages:42 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.atherosclerosis.2020.10.135 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 951 | |a AR | ||
| 952 | |d 315 |j 2020 |h 42 |y 315.2020, e42- | ||
| author_variant |
k n m kn knm |
|---|---|
| matchkey_str |
mohdkasimnanazlisamuhmadhamidimhchuayasa:2020----:ifrnilepneockihbtrhrpirltdohtpolwestlppoeneetreeuainnainsi |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1016/j.atherosclerosis.2020.10.135 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 DE-627 ger DE-627 rakwb eng Mohd Kasim, N.A. verfasserin aut Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nazli, S.A. oth Muhmad Hamidi, M.H. oth Chua, Y.A. oth Sani, H. oth Kasim, S.S. oth Mohd Nawawi, H. oth Enthalten in No title available 315.2020, e42- (DE-627)ELV012595616 (DE-600)1-9150 nnns volume:315 year:2020 pages:42 https://doi.org/10.1016/j.atherosclerosis.2020.10.135 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 AR 315 2020 42 315.2020, e42- |
| spelling |
10.1016/j.atherosclerosis.2020.10.135 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 DE-627 ger DE-627 rakwb eng Mohd Kasim, N.A. verfasserin aut Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nazli, S.A. oth Muhmad Hamidi, M.H. oth Chua, Y.A. oth Sani, H. oth Kasim, S.S. oth Mohd Nawawi, H. oth Enthalten in No title available 315.2020, e42- (DE-627)ELV012595616 (DE-600)1-9150 nnns volume:315 year:2020 pages:42 https://doi.org/10.1016/j.atherosclerosis.2020.10.135 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 AR 315 2020 42 315.2020, e42- |
| allfields_unstemmed |
10.1016/j.atherosclerosis.2020.10.135 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 DE-627 ger DE-627 rakwb eng Mohd Kasim, N.A. verfasserin aut Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nazli, S.A. oth Muhmad Hamidi, M.H. oth Chua, Y.A. oth Sani, H. oth Kasim, S.S. oth Mohd Nawawi, H. oth Enthalten in No title available 315.2020, e42- (DE-627)ELV012595616 (DE-600)1-9150 nnns volume:315 year:2020 pages:42 https://doi.org/10.1016/j.atherosclerosis.2020.10.135 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 AR 315 2020 42 315.2020, e42- |
| allfieldsGer |
10.1016/j.atherosclerosis.2020.10.135 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 DE-627 ger DE-627 rakwb eng Mohd Kasim, N.A. verfasserin aut Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nazli, S.A. oth Muhmad Hamidi, M.H. oth Chua, Y.A. oth Sani, H. oth Kasim, S.S. oth Mohd Nawawi, H. oth Enthalten in No title available 315.2020, e42- (DE-627)ELV012595616 (DE-600)1-9150 nnns volume:315 year:2020 pages:42 https://doi.org/10.1016/j.atherosclerosis.2020.10.135 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 AR 315 2020 42 315.2020, e42- |
| allfieldsSound |
10.1016/j.atherosclerosis.2020.10.135 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 DE-627 ger DE-627 rakwb eng Mohd Kasim, N.A. verfasserin aut Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nazli, S.A. oth Muhmad Hamidi, M.H. oth Chua, Y.A. oth Sani, H. oth Kasim, S.S. oth Mohd Nawawi, H. oth Enthalten in No title available 315.2020, e42- (DE-627)ELV012595616 (DE-600)1-9150 nnns volume:315 year:2020 pages:42 https://doi.org/10.1016/j.atherosclerosis.2020.10.135 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 AR 315 2020 42 315.2020, e42- |
| language |
English |
| source |
Enthalten in No title available 315.2020, e42- volume:315 year:2020 pages:42 |
| sourceStr |
Enthalten in No title available 315.2020, e42- volume:315 year:2020 pages:42 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
No title available |
| authorswithroles_txt_mv |
Mohd Kasim, N.A. @@aut@@ Nazli, S.A. @@oth@@ Muhmad Hamidi, M.H. @@oth@@ Chua, Y.A. @@oth@@ Sani, H. @@oth@@ Kasim, S.S. @@oth@@ Mohd Nawawi, H. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012595616 |
| id |
ELV052543862 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052543862</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624184538.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.atherosclerosis.2020.10.135</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052543862</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0021-9150(20)30717-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mohd Kasim, N.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nazli, S.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muhmad Hamidi, M.H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chua, Y.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sani, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kasim, S.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohd Nawawi, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">No title available</subfield><subfield code="g">315.2020, e42-</subfield><subfield code="w">(DE-627)ELV012595616</subfield><subfield code="w">(DE-600)1-9150</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:315</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.atherosclerosis.2020.10.135</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">315</subfield><subfield code="j">2020</subfield><subfield code="h">42</subfield><subfield code="y">315.2020, e42-</subfield></datafield></record></collection>
|
| author |
Mohd Kasim, N.A. |
| spellingShingle |
Mohd Kasim, N.A. Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| authorStr |
Mohd Kasim, N.A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012595616 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s n sn h m m hm hmm y c yc h s hs s k sk n h m nh nhm |
| hierarchy_parent_title |
No title available |
| hierarchy_parent_id |
ELV012595616 |
| hierarchy_top_title |
No title available |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012595616 (DE-600)1-9150 |
| title |
Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| ctrlnum |
(DE-627)ELV052543862 (ELSEVIER)S0021-9150(20)30717-6 |
| title_full |
Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| author_sort |
Mohd Kasim, N.A. |
| journal |
No title available |
| journalStr |
No title available |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
42 |
| author_browse |
Mohd Kasim, N.A. |
| container_volume |
315 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mohd Kasim, N.A. |
| doi_str_mv |
10.1016/j.atherosclerosis.2020.10.135 |
| title_sort |
differential response to pcsk-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| title_auth |
Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_40 GBV_ILN_105 |
| title_short |
Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia |
| url |
https://doi.org/10.1016/j.atherosclerosis.2020.10.135 |
| remote_bool |
true |
| author2 |
Nazli, S.A. Muhmad Hamidi, M.H. Chua, Y.A. Sani, H. Kasim, S.S. Mohd Nawawi, H. |
| author2Str |
Nazli, S.A. Muhmad Hamidi, M.H. Chua, Y.A. Sani, H. Kasim, S.S. Mohd Nawawi, H. |
| ppnlink |
ELV012595616 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.atherosclerosis.2020.10.135 |
| up_date |
2024-07-06T23:19:07.922Z |
| _version_ |
1803873626801307648 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052543862</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624184538.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.atherosclerosis.2020.10.135</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052543862</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0021-9150(20)30717-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mohd Kasim, N.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nazli, S.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muhmad Hamidi, M.H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chua, Y.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sani, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kasim, S.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohd Nawawi, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">No title available</subfield><subfield code="g">315.2020, e42-</subfield><subfield code="w">(DE-627)ELV012595616</subfield><subfield code="w">(DE-600)1-9150</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:315</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.atherosclerosis.2020.10.135</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">315</subfield><subfield code="j">2020</subfield><subfield code="h">42</subfield><subfield code="y">315.2020, e42-</subfield></datafield></record></collection>
|
| score |
7.4007235 |